Cytogenetic response by relative risk
. | Complete cytogenetic response, % . | . | . | ||
|---|---|---|---|---|---|
| Relative risk . | Low . | Intermediate . | High . | ||
| Italian multicenter study: 77 patients, 400 mg IM, response at 6 mo171 | 70 | 41 | 8 | ||
| International multicenter IRIS study: 383 patients, 400 mg IM | |||||
| Response at 12 mo53 | 76 | 67 | 49 | ||
| Response at 42 mo172 | 91 | 84 | 69 | ||
| Single-center study: 187 patients, 400-800 mg IM, overall response54 | 84 | 85 | 69 | ||
. | Complete cytogenetic response, % . | . | . | ||
|---|---|---|---|---|---|
| Relative risk . | Low . | Intermediate . | High . | ||
| Italian multicenter study: 77 patients, 400 mg IM, response at 6 mo171 | 70 | 41 | 8 | ||
| International multicenter IRIS study: 383 patients, 400 mg IM | |||||
| Response at 12 mo53 | 76 | 67 | 49 | ||
| Response at 42 mo172 | 91 | 84 | 69 | ||
| Single-center study: 187 patients, 400-800 mg IM, overall response54 | 84 | 85 | 69 | ||
Two independent studies of newly diagnosed patients in ECP who were treated initially with 400 mg IM daily have shown that the cytogenetic and the molecular response to that dose of IM was significantly related to risk according to Sokal et al.24 In 1 study171 the relationship was found also using risk according to Hasford et al.25 In another study54 the differences were not significant, but IM dose was higher: 800 mg in 100 patients, 600 mg in 14 patients, and 400 mg in 73 patients. The last update of the IRIS study58 reported OS was also risk related: 94% for low-risk patients, 88% for intermediate-risk patients, and 81% for high-risk patients (P < .001) after 54 months of therapy.